*Phase 3 development programs:
Positive results in first Phase 3 Dravet syndrome trial
Positive results in first Phase 3 LGS trial
Data presentations expected at upcoming American Epilepsy Society Annual Meeting in December
Positive Dravet syndrome Pre-NDA meeting held with FDA
NDA on track for H1 2017 submission for both Dravet and LGS indications
Data from second LGS trial expected at end of Q3
Second Phase 3 Dravet syndrome trial ongoing
Phase 3 trial in TSC ongoing
Phase 3 trial in IS to commence in Q4 2016
*Positive results in first Phase 3 Dravet syndrome trial
*Positive results in first Phase 3 LGS trial
*Data presentations expected at upcoming American Epilepsy Society Annual Meeting in December
*Positive Dravet syndrome Pre-NDA meeting held with FDA
*NDA on track for H1 2017 submission for both Dravet and LGS indications
*Data from second LGS trial expected at end of Q3
*Second Phase 3 Dravet syndrome trial ongoing
*Phase 3 trial in TSC ongoing
*Phase 3 trial in IS to commence in Q4 2016
*Expanded access program and open label extension:
Over 1,000 patients now on Epidiolex treatment under Expanded Access Treatment INDs, U.S. State programs, and open label extension trial
*Over 1,000 patients now on Epidiolex treatment under Expanded Access Treatment INDs, U.S. State programs, and open label extension trial
*Advanced clinical programs in multiple cannabinoid pipeline product candidates:
*CBDV Phase 2 partial-onset epilepsy study in adults ongoing. Part A complete and Part B underway with data expected H1 2017
*CBDV pre-clinical research ongoing within field of autism spectrum disorders. Initial open-label clinical evaluation expected to commence in H2 2016, with Phase 2 trials expected to commence in H1 2017
*Neonatal Hypoxic-Ischemic Encephalopathy (NHIE) intravenous CBD Phase 1 clinical program expected to commence in Q4 2016
*Orphan Drug and Fast Track Designations granted from FDA and EMA
*THC:CBD Phase 1b/2a study for the treatment of Recurrent Glioblastoma Multiforme (GBM) fully enrolled with data expected in Q4 2016
*Sativex® Phase 2 study in children with spasticity due to cerebral palsy fully enrolled with data expected Q4 2016
*THCV Phase 2 study in type 2 diabetes completed, primary
endpoint not achieved
70